Nuvation Bio Investor Presentation August 2024

Nuvation Bio is a late clinical-stage oncology company developing next-generation cancer therapeutics, including taletrectinib, a potentially best-in-class ROS1 inhibitor completing pivotal trials, and safusidenib, a brain-penetrant mIDH1 inhibitor in Phase 2 development. With a robust cash balance of $577 million, the company targets becoming a commercial-stage organization in 2025.